Esta referencia está disponible actualmente en inglés. La versión en español está en preparación.
SNAP-8 and Acetyl Hexapeptide-8: What the Cosmetic Studies Report
Por Benn Bluestein-Veyra, M.Sc. en Química Orgánica · Actualizado el 9 de noviembre de 2026
ExaVeyra Sciences es un proveedor B2B con sede en Miami que suministra exosomas para uso estético tópico a clínicas con licencia, y trabaja con una farmacia de preparados compuestos 503A que prepara formulaciones para prescriptores con licencia según prescripciones individuales.
| Pregunta | Respuesta |
|---|---|
| Qué cubre esta página | SNAP-8 peptide evidence: what the cosmetic studies of acetyl hexapeptide-8 and acetyl octapeptide-3 report, the penetration data, and the FDA cosmetic frame. |
| Quién puede hacer pedidos | Clínicas y profesionales con licencia profesional activa y NPI verificados por ExaVeyra. Los pedidos de exosomas requieren además un reconocimiento firmado de uso profesional. |
| Qué se envía y cómo | Las formulaciones compuestas las prepara y dispensa nuestra farmacia asociada 503A según una prescripción individual del profesional con licencia, y se envían desde la farmacia. Las sustancias controladas las dispensa la farmacia con su propio registro de la DEA. |
Acetyl hexapeptide-8, sold as Argireline, is a six-residue peptide patterned on the N-terminal region of SNAP-25, and SNAP-8 (acetyl octapeptide-3) is the same sequence extended by two residues. The published evidence belongs almost entirely to the hexapeptide: a 2002 report by its designers describing reduced wrinkle depth in volunteers and SNARE complex interference in vitro, a randomized placebo-controlled trial of 60 Chinese subjects in 2013, a 24-volunteer randomized study in 2017, and penetration studies, one by FDA scientists, that found the peptide largely confined to the stratum corneum.[1][2][3][4] In 2025 the Cosmetic Ingredient Review Expert Panel concluded that acetyl hexapeptide-8 amide is safe in cosmetics "in the present practices of use at concentrations up to 0.005%" and that the data are insufficient for a determination at higher concentrations.[5] As of 8 November 2026, PubMed holds no controlled trial of acetyl octapeptide-3 on its own.[6][7]
Both peptides are marketed as cosmetic ingredients. FDA states that cosmetic products and ingredients, other than color additives, need no premarket approval, and that a product intended to affect the structure or function of the skin is a drug, or sometimes a medical device, even if it affects appearance.[8][9] This page reports what the studies and the agency state, and keeps the two molecules apart.
SNARE proteins drive vesicle fusion, and SNAP-25 contributes two of the four helices
Neurotransmitter release depends on soluble N-ethylmaleimide-sensitive factor attachment protein receptors, the SNAREs, which Jahn, Cafiso and Tamm describe as "a family of small conserved eukaryotic proteins that mediate membrane fusion between organelles and with the plasma membrane" that assemble between membranes "with the aid of accessory proteins that provide a scaffold to initiate SNARE zippering, pulling the membranes together and mediating fusion."[10] In the neuronal complex, syntaxin-1 and synaptobrevin each supply one helix and SNAP-25 supplies two, so a peptide resembling part of SNAP-25 could in principle compete for a position in the bundle.[10]
That is the premise behind both peptides. Blanes-Mira and colleagues reported in 2002 that the hexapeptide Ac-EEMQRR-NH2 "significantly inhibited neurotransmitter release with a potency similar to that of BoNT A, although as expected, it displayed much lower efficacy than the neurotoxin", through "interference of the hexapeptide with the formation and/or stability" of the SNARE complex.[1] Wang and colleagues restated the mechanism in 2013: the peptide "is patterned from the N-terminal end of the protein SNAP-25" and "is reported to inhibit vesicle docking by preventing formation of the ternary SNARE complex."[2]
Acetyl hexapeptide-8 and SNAP-8 are two molecules with two very different literatures
Acetyl hexapeptide-8 is the INCI name for Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2; older papers call it acetyl hexapeptide-3, and the CIR Expert Panel notes that "Acetyl Hexapeptide-8 Amide" is "synonymous with Acetyl Hexapeptide-8 (sans "Amide")".[5][11] SNAP-8 is the trade name of acetyl octapeptide-3, recorded in PubChem as Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2, the hexapeptide extended by alanine and aspartate at its C-terminus.[12] The randomized trials, penetration studies and safety assessment on this page concern the hexapeptide; the two studies that include the octapeptide are described separately below.[6][7][11]
| Item | Acetyl hexapeptide-8 (Argireline) | SNAP-8 (acetyl octapeptide-3) |
|---|---|---|
| Sequence | Ac-EEMQRR-NH2, six residues | Ac-EEMQRRAD-NH2, eight residues |
| Design premise | Mimic of the SNAP-25 N-terminal region | The same mimic extended by two residues |
| Randomized trials of the peptide alone | Wang 2013 (60 subjects), Raikou 2017 (24 volunteers), Lungu 2013 (24 patients) | None indexed in PubMed as of 8 November 2026 |
| Skin penetration studies | Kraeling 2015, Hoppel 2015, Lim 2018 | None indexed |
| Safety assessment | CIR Expert Panel 2025 | None indexed |
| Other human data | One injection case report (Chen 2021) | Two multi-ingredient microneedle patch studies (Avcil 2020, Shin 2024) |
What the randomized trials of acetyl hexapeptide-8 report
The designers' 2002 report described a skin topography study in which an oil-in-water emulsion containing 10% of the hexapeptide, applied to healthy women volunteers for 30 days, "reduced wrinkle depth up to 30%"; the number of volunteers is absent from the indexed abstract.[1]
Wang and colleagues randomized 60 Chinese subjects to the hexapeptide or placebo in a 3 to 1 ratio, applied to periorbital wrinkles over four weeks, and assessed the result by clinical grading and by silicone replicas read with a wrinkle-analysis instrument.[2] They reported "total anti-wrinkle efficacy in the argireline group" of 48.9 percent against 0 percent for placebo on the subjective scale, and that "the parameters of roughness were all decreased in the argireline group" with no obvious decrease under placebo.[2] The abstract does not describe blinding or report adverse events.[2]
Raikou and colleagues randomized 24 healthy volunteers to four groups over 60 days: acetyl hexapeptide-3 with tripeptide-10 citrulline, either peptide alone, or neither.[3] Skin microtopography and transepidermal water loss differed between several group pairs at 20, 40 and 60 days, and the authors concluded that the results "confirm the antiwrinkle activity of acetyl hexapeptide-3" with "a significant decrease in TEWL", while the mechanism of any synergy "was not clear in this study."[3] Twenty-four volunteers across four groups makes this a small study.[3]
A third randomized trial used the peptide outside cosmetics. Lungu and colleagues at the NIH ran a double-blind, placebo-controlled pilot of daily topical acetyl hexapeptide-8 in 24 patients with blepharospasm who were receiving botulinum toxin injections.[13] They reported "no significant adverse events" and "a trend for longer time until return to baseline" in the active group (3.7 months against 3.0), and described the result as a trend in a pilot study.[13]
A 2025 review by Zdrada-Nowak and colleagues summarized the clinical literature: "Preclinical and clinical studies indicate that AH-8 may reduce wrinkle depth, improve skin elasticity, and enhance hydration. However, the precise biological mechanisms underlying these effects-particularly the peptide's ability to inhibit muscle contraction when applied topically-remain incompletely understood."[11]
Penetration studies found the hexapeptide mostly in the stratum corneum
Whether a hydrophilic peptide of relatively large molecular weight crosses intact stratum corneum is the question the penetration literature set out to answer.[14] Kraeling and colleagues at FDA's Center for Food Safety and Applied Nutrition applied an oil-in-water cosmetic emulsion containing 10% commercially available acetyl hexapeptide-8 to hairless guinea pig and human cadaver skin in diffusion cells for 24 hours, then measured the peptide layer by layer by liquid chromatography and tandem mass spectrometry.[4] They reported that "the majority of the Ac-EEMQRR-amide was washed from the surface of both HGP and human skin", that the peptide that did penetrate "remained mostly in the stratum corneum" (0.54 percent of the applied dose in guinea pig skin and 0.22 percent in human skin), and that "No peptide was detected in the dermis or buffer collected underneath the skin for both human and HGP."[4]
Hoppel and colleagues, working with porcine ear skin, found that the vehicle matters: a multiple water-in-oil-in-water emulsion "can significantly increase penetration of AH-8 into porcine skin compared to simple O/W and W/O emulsions", and they described the peptide's penetration as "sparsely studied and controversially discussed."[15] Lim and colleagues reported that the peptide "exists in zwitterionic form and this charged state hindered its skin permeation", and that two modified analogues permeated human skin better in vitro.[14]
The 2025 review drew the strands together: the peptide "faces limited permeability through the lipophilic stratum corneum", and "the ability of AH-8 to reach neuromuscular junctions remains uncertain."[11] As of 8 November 2026, PubMed indexes no penetration study of acetyl octapeptide-3; the only two studies that include it delivered it by microneedle patch.[6][7]
The Cosmetic Ingredient Review Panel set a concentration limit for its safety conclusion
The Expert Panel for Cosmetic Ingredient Safety published its assessment of acetyl hexapeptide-8 amide in 2025. The Panel recorded that the ingredient "is reported to function as a skin conditioning agent - miscellaneous in cosmetics" and "concluded that Acetyl Hexapeptide-8 Amide is safe in cosmetics in the present practices of use at concentrations up to 0.005%."[5] It "further concluded that the available data are insufficient to make a determination that Acetyl Hexapeptide-8 Amide is safe under the intended conditions of use in cosmetic formulations at concentrations greater than 0.005%."[5] The Panel's conclusion is a cosmetic ingredient safety review; FDA does not approve cosmetic ingredients other than color additives before marketing.[5][8]
One safety report concerns a route the cosmetic studies never used. Chen and colleagues described a woman who received acetyl hexapeptide-8 injections in the forehead and temples and developed erythema, nodules and abscesses at the injection sites after one week; cultures grew Mycobacterium abscessus.[16] The authors framed the case as a procedure-related infection rather than a finding about the peptide.[16]
SNAP-8 appears in two multi-ingredient microneedle studies and in no trial of its own
As of 8 November 2026, PubMed returns no randomized trial, penetration study or safety assessment of acetyl octapeptide-3 alone. The peptide appears in two clinical studies of dissolving hyaluronic acid microneedle patches, each combining it with several other actives. Avcil and colleagues tested a patch loaded with "arginine/lysine polypeptide, acetyl octapeptide-3, palmitoyl tripeptide-5, adenosine, and seaweed extracts" in healthy subjects with aged skin over 12 weeks, reported that "none of the subjects reported any primary or cumulative skin reactions", and measured a 25.8 percent decrease in fine lines and wrinkles.[6] Shin and colleagues enrolled 24 healthy subjects in a placebo-patch comparison of a patch containing acetyl octapeptide-3 with two other actives, applied overnight to one eye with placebo on the other, and reported improved eye wrinkles, reduced transepidermal water loss and "no adverse effects" at 28 days.[7]
Neither study can attribute its result to the octapeptide, because microneedles bypass the stratum corneum that confines a topical peptide and because every patch carried several actives.[6][7] A reader weighing SNAP-8 therefore has established target biology, hexapeptide data that belong to a different molecule, and two formulation studies that do not isolate it.[10][11]
FDA regulates cosmetics by intended use, and anti-wrinkle claims sit on the line
The FD&C Act defines a cosmetic as "articles intended to be rubbed, poured, sprinkled, or sprayed on, introduced into, or otherwise applied to the human body or any part thereof for cleansing, beautifying, promoting attractiveness, or altering the appearance", and a drug to include "articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease" and "articles (other than food) intended to affect the structure or any function of the body of man or other animals."[17] FDA states that "Whether a product is a cosmetic or a drug under the law is determined by a product's intended use", established by claims, consumer perception and ingredients, and that "The FD&C Act does not recognize any such category as “cosmeceuticals.”"[18][19]
On wrinkle products specifically, FDA states: "if a product is intended to make lines and wrinkles less noticeable, simply by moisturizing the skin, it's a cosmetic", whereas "if a product is intended, for example, to remove wrinkles or increase the skin's production of collagen, it's a drug or a medical device."[9] The agency adds that it "is concerned about drug claims made for products marketed as cosmetics, such as skin care products with anti-wrinkle or anti-aging claims that involve supposed effects on the structure or function of the skin."[9] A claim that a peptide relaxes facial muscles or blocks neurotransmitter release describes an effect on the function of the body, the drug side of that line as FDA draws it.[9][18]
Cosmetics need no FDA approval before marketing and FDA keeps no list of approved claims, but "information on cosmetic labeling, including claims, must be truthful and not misleading", and firms "have a legal responsibility to ensure the safety of their products."[8][20] Under 21 CFR 740.10, each ingredient and finished cosmetic "shall be adequately substantiated for safety prior to marketing", and an unsubstantiated product is misbranded unless its principal display panel warns that the safety of the product has not been determined.[21] Under 21 CFR 701.3, the label must declare each ingredient "in descending order of predominance."[22] The Modernization of Cosmetics Regulation Act of 2022 added facility registration, product listing, safety substantiation and serious adverse event reporting within 15 business days, and gave FDA mandatory recall authority, on which FDA issued a final guidance on 29 October 2026.[23]
How the sources frame a compounded serum that contains these peptides
The studies above are cosmetic ingredient studies, and the regulatory frame above governs cosmetics sold to consumers. A practitioner reading them for a peptide serum would take from the literature the points below, and from FDA that the claims made for a product determine its regulatory category.[2][3][4][5][13][14][15][18]
- The randomized trials of acetyl hexapeptide-8 enrolled 24 to 60 participants; the two cosmetic trials ran four weeks and 60 days, and the NIH pilot followed patients until symptoms returned to baseline, about three to four months on average.
- The FDA penetration study found no hexapeptide in the dermis or receptor fluid after 24 hours; one vehicle study showed that emulsion structure changes delivery, and a second showed that modified analogues of the peptide permeated human skin better in vitro.
- The CIR Panel's 2025 safety conclusion applies to reported use concentrations up to 0.005 percent and the Panel found the data insufficient above that.
- Acetyl octapeptide-3 has no indexed trial, penetration study or safety assessment of its own as of 8 November 2026.
Section 503A of the FD&C Act permits a pharmacist to compound with a bulk drug substance only if it complies with an applicable USP or NF monograph, is a component of an FDA-approved drug, or appears on FDA's 503A bulks list, and is accompanied by a valid certificate of analysis.[24] Whether acetyl octapeptide-3 meets that test is a determination the dispensing pharmacy makes. ExaVeyra's GHK-Cu, SNAP-8 and niacinamide serum reaches a practice through a licensed 503A pharmacy partner on a patient-specific prescription, with a certificate of analysis for each lot available on request. Whether to prescribe it, how to describe it and how to document the decision are matters for the practitioner, read against the studies and the FDA statements reported here.
This article summarizes publicly available federal regulation for licensed practitioner education. It is not legal advice, medical advice, or regulatory guidance, and it does not establish that any particular product or practice is compliant. Confirm current federal and state obligations with qualified counsel.
Referencias comentadas
Numeradas en el orden en que se citan en el texto. Cada fuente lleva una nota sobre lo que respalda en esta página; los artículos revisados por pares se listan con revista, volumen, número y páginas, y las fuentes primarias son regulaciones, documentos de agencias, guías y declaraciones de posición.
- 1.Peer-reviewedBlanes-Mira C, Clemente J, Jodas G, Gil A, Fernández-Ballester G, Ponsati B, Gutierrez L, Pérez-Payá E, Ferrer-Montiel A. A synthetic hexapeptide (Argireline) with antiwrinkle activity. International Journal of Cosmetic Science. 2002;24(5):303-310. https://pubmed.ncbi.nlm.nih.gov/18498523/Annotation: The designers' report: rational design of Ac-EEMQRR-NH2, SNARE complex interference and inhibition of neurotransmitter release in vitro, and the 30-day volunteer skin topography study.
- 2.Peer-reviewedWang Y, Wang M, Xiao S, Pan P, Li P, Huo J. The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study. American Journal of Clinical Dermatology. 2013;14(2):147-153. https://pubmed.ncbi.nlm.nih.gov/23417317/Annotation: The randomized placebo-controlled trial of acetyl hexapeptide-8 on periorbital wrinkles: design, subjective and replica-based outcomes, and the SNAP-25 mechanism as the authors state it.
- 3.Peer-reviewedRaikou V, Varvaresou A, Panderi I, Papageorgiou E. The efficacy study of the combination of tripeptide-10-citrulline and acetyl hexapeptide-3. A prospective, randomized controlled study. Journal of Cosmetic Dermatology. 2017;16(2):271-278. https://pubmed.ncbi.nlm.nih.gov/28150423/Annotation: The four-arm randomized study of acetyl hexapeptide-3 alone and with tripeptide-10 citrulline over 60 days: microtopography and transepidermal water loss outcomes and the authors' conclusion.
- 4.Peer-reviewedKraeling ME, Zhou W, Wang P, Ogunsola OA. In vitro skin penetration of acetyl hexapeptide-8 from a cosmetic formulation. Cutaneous and Ocular Toxicology. 2015;34(1):46-52. https://pubmed.ncbi.nlm.nih.gov/24754410/Annotation: The FDA diffusion-cell study in human cadaver and hairless guinea pig skin: peptide confined mostly to the stratum corneum, none detected in the dermis or receptor fluid.
- 5.Peer-reviewedJohnson W Jr, Bergfeld WF, Belsito DV, Cohen DE, Klaassen CD, Liebler DC, Marks JG Jr, Peterson LA, Shank RC, Slaga TJ, Snyder PW, Fiume M, Heldreth B. Safety Assessment of Acetyl Hexapeptide-8 Amide as Used in Cosmetics. International Journal of Toxicology. 2025;44(2_suppl):54S-63S. https://pubmed.ncbi.nlm.nih.gov/40673537/Annotation: The Cosmetic Ingredient Review Expert Panel conclusion: safe in present practices of use up to 0.005 percent, data insufficient above that, and the synonymy of acetyl hexapeptide-8 and its amide.
- 6.Peer-reviewedAvcil M, Akman G, Klokkers J, Jeong D, Çelik A. Efficacy of bioactive peptides loaded on hyaluronic acid microneedle patches: A monocentric clinical study. Journal of Cosmetic Dermatology. 2020;19(2):328-337. https://pubmed.ncbi.nlm.nih.gov/31134751/Annotation: One of two indexed human studies that include acetyl octapeptide-3, in a multi-ingredient hyaluronic acid microneedle patch over 12 weeks; tolerability and instrumental skin measurements as reported.
- 7.Peer-reviewedShin JY, Han D, Yoon KY, Jeong DH, Park YI. Clinical Safety and Efficacy Evaluation of a Dissolving Microneedle Patch Having Dual Anti-Wrinkle Effects With Safe and Long-Term Activities. Annals of Dermatology. 2024;36(4):215-224. https://pubmed.ncbi.nlm.nih.gov/39082657/Annotation: The placebo-patch comparison of a dissolving microneedle patch containing acetyl octapeptide-3 with two other actives over 28 days; the second of the two indexed human studies that include the octapeptide.
- 8.RegulatoryFDA, FDA Authority Over Cosmetics: How Cosmetics Are Not FDA-Approved, but Are FDA-Regulated (content current 18 November 2025). Accessed 8 November 2026. https://www.fda.gov/cosmetics/cosmetics-laws-regulations/fda-authority-over-cosmetics-how-cosmetics-are-not-fda-approved-are-fda-regulated
- 9.RegulatoryFDA, Wrinkle Treatments and Other Anti-aging Products (content current 25 February 2022). Accessed 8 November 2026. https://www.fda.gov/cosmetics/cosmetic-products/wrinkle-treatments-and-other-anti-aging-products
- 10.Peer-reviewedJahn R, Cafiso DC, Tamm LK. Mechanisms of SNARE proteins in membrane fusion. Nature Reviews Molecular Cell Biology. 2024;25(2):101-118. https://pubmed.ncbi.nlm.nih.gov/37848589/Annotation: The SNARE fusion mechanism, zippering and accessory proteins, cited for the target biology both peptides are premised on rather than as evidence about either peptide.
- 11.Peer-reviewedZdrada-Nowak J, Surgiel-Gemza A, Szatkowska M. Acetyl Hexapeptide-8 in Cosmeceuticals-A Review of Skin Permeability and Efficacy. International Journal of Molecular Sciences. 2025;26(12):5722. https://pubmed.ncbi.nlm.nih.gov/40565185/Annotation: The 2025 review of acetyl hexapeptide-8 structure, mechanism, clinical findings and skin permeability, including its statements that delivery to the neuromuscular junction remains uncertain.
- 12.DatabaseNational Library of Medicine, PubChem Compound Summary for CID 76283482, Acetyl octapeptide-3. Accessed 9 November 2026. https://pubchem.ncbi.nlm.nih.gov/compound/76283482
- 13.Peer-reviewedLungu C, Considine E, Zahir S, Ponsati B, Arrastia S, Hallett M. Pilot study of topical acetyl hexapeptide-8 in the treatment for blepharospasm in patients receiving botulinum toxin therapy. European Journal of Neurology. 2013;20(3):515-518. https://pubmed.ncbi.nlm.nih.gov/23146065/Annotation: The NIH double-blind placebo-controlled pilot of daily topical acetyl hexapeptide-8 in patients receiving botulinum toxin: no significant adverse events and a trend in time to return to baseline.
- 14.Peer-reviewedLim SH, Sun Y, Thiruvallur Madanagopal T, Rosa V, Kang L. Enhanced Skin Permeation of Anti-wrinkle Peptides via Molecular Modification. Scientific Reports. 2018;8(1):1596. https://pubmed.ncbi.nlm.nih.gov/29371611/Annotation: The zwitterion explanation for poor skin permeation of acetyl hexapeptide-8 and the in vitro comparison of modified analogues in human skin and stem-cell-derived neurons.
- 15.Peer-reviewedHoppel M, Reznicek G, Kählig H, Kotisch H, Resch GP, Valenta C. Topical delivery of acetyl hexapeptide-8 from different emulsions: influence of emulsion composition and internal structure. European Journal of Pharmaceutical Sciences. 2015;68:27-35. https://pubmed.ncbi.nlm.nih.gov/25497319/Annotation: The porcine skin vehicle study: multiple water-in-oil-in-water emulsions increased penetration compared with simple emulsions, and the authors' description of the penetration literature as sparse and contested.
- 16.Peer-reviewedChen CF, Liu J, Wang SS, Yao YF, Yu B, Hu XP. Mycobacterium abscessus infection after facial injection of argireline: A case report. World Journal of Clinical Cases. 2021;9(8):1996-2000. https://pubmed.ncbi.nlm.nih.gov/33748252/Annotation: The first reported case of Mycobacterium abscessus infection after facial injection of acetyl hexapeptide-8, reported as the authors frame it: a procedure-related infection.
- 17.Regulatory21 U.S.C. 321, Definitions; generally, paragraphs (g)(1) and (i) (United States Code, 2024 edition, GPO). Accessed 8 November 2026. https://www.govinfo.gov/content/pkg/USCODE-2024-title21/html/USCODE-2024-title21-chap9-subchapII-sec321.htm
- 18.RegulatoryFDA, Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?) (content current 11 September 2024). Accessed 8 November 2026. https://www.fda.gov/cosmetics/cosmetics-laws-regulations/it-cosmetic-drug-or-both-or-it-soap
- 19.RegulatoryFDA, "Cosmeceutical" (cosmetics labeling claims; content current 25 February 2022). Accessed 8 November 2026. https://www.fda.gov/cosmetics/cosmetics-labeling-claims/cosmeceutical
- 20.RegulatoryFDA, Cosmetics Labeling Claims (content current 21 November 2022). Accessed 8 November 2026. https://www.fda.gov/cosmetics/cosmetics-labeling/cosmetics-labeling-claims
- 21.Regulatory21 CFR 740.10, Labeling of cosmetic products for which adequate substantiation of safety has not been obtained (eCFR, current through 5 November 2026). Accessed 8 November 2026. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-G/part-740/subpart-A/section-740.10
- 22.Regulatory21 CFR 701.3, Designation of ingredients (eCFR, current through 5 November 2026). Accessed 8 November 2026. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-G/part-701/subpart-A/section-701.3
- 23.RegulatoryFDA, Modernization of Cosmetics Regulation Act of 2022 (MoCRA) (content current 29 October 2026). Accessed 8 November 2026. https://www.fda.gov/cosmetics/cosmetics-laws-regulations/modernization-cosmetics-regulation-act-2022-mocra
- 24.Regulatory21 U.S.C. 353a, Pharmacy compounding, subsection (b)(1)(A) (United States Code, 2024 edition, GPO). Accessed 9 November 2026. https://www.govinfo.gov/content/pkg/USCODE-2024-title21/html/USCODE-2024-title21-chap9-subchapV-partA-sec353a.htm
Cite this page
ExaVeyra Sciences Editorial Team. SNAP-8 and Acetyl Hexapeptide-8: Studies. ExaVeyra Sciences; 9 November 2026. Available from: https://exaveyra.com/science/compounds/snap-8-acetyl-hexapeptide-studies. Accessed [date accessed].